DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Alglucosidase alfa
Alglucosidase alfa
AHFS Pharmacologic-Therapeutic Classification System
WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T
Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
Cipaglucosidase Alfa/Miglustat Phase 3 PROPEL Results
Myozyme, INN-Alglucosidase Alfa
Vivian Oh, Et Al. V. Genzyme Corporation, Et Al. OH-Class Action
Enzyme Replacement LSD Combined Policy
Estonian Statistics on Medicines 2016 1/41
Treatment Protocol – Information for Healthcare Professionals
Lists of Medicinal Products for Rare Diseases in Europe*
May2013 CPG Updates
Specialty Medications That Unitypoint at Home Specialty Pharmacy Can Provide Or Facilitate Access to and Is Subject to Change
MYOZYME (Alglucosidase Alfa) RATIONALE for INCLUSION IN
Lysosomal Storage Disorders Medical Drug Program Summary
TREATMENTS for POMPE DISEASE What’S in the Toolbox Now, and What Is Still Under Construction SCOTT A
Lysosomal Storage Disorders
CDER List of Licensed Biological Products With
Top View
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
Print Annual Reviews for Fiscal Year 2018
Specialty Pharmacy Medications
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
Estonian Statistics on Medicines 2017 1/42
EPAR, INN-Alglucosidase Alfa
Pompe-Position-Statement.Pdf
5.01.576 Drugs for Rare Diseases
Alglucosidase Alfa (Lumizyme, Myozyme) Reference Number: ERX.SPMN.144 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
Media Update
Aralast NP™, Glassia™, Prolastin®-C
ATB200/AT2221 for Late Onset Pompe Disease in Adults and Adolescents >12 Years –
Alglucosidase Alfa), for Injection, for Intravenous Use and Hypersensitivity Reactions Have Been Observed in Some Patients During Initial U.S
Enzyme Related Therapies
A Baker's Dozen of US FDA E Cacy Approvals Using Real World
Corporate Medical Policy
TRANSPARENCY COMMITTEE Opinion 9 January 2013
Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders
Health Plan Insights
Efficacy and Safety of Cipaglucosidase Alfa/Miglustat Versus Alglucosidase Alfa in Late-Onset Pompe Disease: a Global, Double-Blind, Randomized Phase 3 Trial (PROPEL)
The Legally Binding Text Is the Original French Version TRANSPARENCY
Alglucosidase Alfa) • None (4)
Public Summary of Opinion on Orphan Designation: Miglustat For
Late-Onset Pompe Disease
Appendix A: Perioperative Medication Management
Improved Efficacy of a Next-Generation ERT in Murine Pompe Disease
WHAT DOES the NEW ONTARIO PHARMACARE PLAN OFFER CHILDREN and YOUNG ADULTS with RARE DISORDERS? by Nigel S
Specialty Drug List
AHFS Pharmacologic-Therapeutic Classification System
The Main Tea Eta a a a a a a a Maria Martin
11 Pdf [488 K]
Medimpact April 2019 Specialty Drug List
Poster Session Abstracts
Enzyme Replacement Therapy
Complement Inhibitor and Enzyme/Protein Replacement Therapy
Pressure for Drug Development in Lysosomal Storage
Lumizyme (Alglucosidase Alfa)
Do Not Tube List
Form 20-F 2020 | 1 Part I Item 3
Worldsymposium 2021 Poster List
Sanofi Genzyme Commitment to Patients with Rare Diseases Highlighted at Worldsymposium 2017
Assessing Metabolic Profiles in Human Myoblasts from Patients with Late-Onset Pompe Disease
Issue and Citation Type: M= Main Feature; L= Literature Review; F= FDA Update; C= Correction)
Specialty Pharmacy Drug List Specialty Medications List
Tenofovir Alafenamide
Specialty Drug List
Early Access to Medicines Scheme – Treatment Protocol – Information for Healthcare Professionals
Pregnancy Outcomes in Late Onset Pompe Disease
Myozyme 50 Mg for Intravenous Drip Infusion [Non-Proprietary Name] Alglucosidase Alfa (Genetical Recombination) (JAN*) [Applicant] Genzyme Japan K.K
Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease
November 2020
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
Alglucosidase Alfa: First Available Treatment for Pompe Disease
2019 Medicaid Preapproval Criteria
CHMP Agenda of the 19-22 July 2021 Meeting